DWD 81.09(3)(d)1.a. a. Time for treatment response is 2 to 4 treatments.
DWD 81.09(3)(d)1.b. b. Maximum treatment frequency is up to 5 times per week for the first one to 3 weeks, decreasing in frequency until the end of the maximum treatment duration period in subd. 1. c.
DWD 81.09(3)(d)1.c. c. Maximum treatment duration is 12 weeks of treatment in a clinical setting but only if given in conjunction with other therapies.
DWD 81.09(3)(d)2. 2. Home use of thermal modalities may be prescribed at any time during the course of treatment. Home use may only involve hot packs, hot soaks, hot water bottles, hydrocollators, heating pads, ice packs, and cold soaks that can be applied by the patient without health care provider assistance. Home use of thermal modalities may not require any special training or monitoring, other than that usually provided by a health care provider during an office visit.
DWD 81.09(3)(e) (e) Electrical muscle stimulation. For purposes of this paragraph, “electrical muscle stimulation" includes galvanic stimulation, transcutaneous electrical nerve stimulation, interferential and microcurrent techniques. All of the following guidelines apply to electrical muscle stimulation:
DWD 81.09(3)(e)1. 1. Treatment given in a clinical setting:
DWD 81.09(3)(e)1.a. a. Time for treatment response is 2 to 4 treatments.
DWD 81.09(3)(e)1.b. b. Maximum treatment frequency is up to 5 times per week for the first one to 3 weeks, decreasing in frequency until the end of the maximum treatment duration period in subd. 1. c.
DWD 81.09(3)(e)1.c. c. Maximum treatment duration is 12 weeks of treatment in a clinical setting but only if given in conjunction with other therapies.
DWD 81.09(3)(e)2. 2. Home use of an electrical muscle stimulation device may be prescribed at any time during a course of treatment. Initial use of an electrical stimulation device shall be in a supervised setting in order to ensure proper electrode placement and patient education. All of the following guidelines apply to home use of an electrical stimulation device:
DWD 81.09(3)(e)2.a. a. Time for patient education and training is one to 3 sessions.
DWD 81.09(3)(e)2.b. b. Patient may use the electrical stimulation device unsupervised for one month, at which time effectiveness of the treatment shall be reevaluated by a health care provider before continuing home use of the device.
DWD 81.09(3)(f) (f) Acupuncture treatments. For purposes of this paragraph, “acupuncture treatments" include endorphin-mediated analgesic therapy that includes classic acupuncture and acupressure. All of the following guidelines apply to acupuncture treatments:
DWD 81.09(3)(f)1. 1. Time for treatment response is 3 to 5 sessions.
DWD 81.09(3)(f)2. 2. Maximum treatment frequency is up to 3 times per week for the first one to 3 weeks, decreasing in frequency until the end of the maximum treatment duration period in subd. 3.
DWD 81.09(3)(f)3. 3. Maximum treatment duration is 12 weeks.
DWD 81.09(3)(g) (g) Phoresis. For purposes of this paragraph, “phoresis" includes phonopheresis and iontophoresis. All of the following guidelines apply to phoresis:
DWD 81.09(3)(g)1. 1. Time for treatment response is 3 to 5 sessions.
DWD 81.09(3)(g)2. 2. Maximum treatment frequency is up to 3 times per week for the first one to 3 weeks, decreasing in frequency until the end of the maximum treatment duration period in subd. 3.
DWD 81.09(3)(g)3. 3. Maximum treatment duration is 9 sessions of either iontophoresis or phonophoresis, or combination, to any one site, with a maximum duration of 12 weeks for all treatment.
DWD 81.09(3)(h) (h) Manual therapy. For purposes of this paragraph, “manual therapy" includes soft tissue and joint mobilization and therapeutic massage. All of the following guidelines apply to manual therapy:
DWD 81.09(3)(h)1. 1. Time for treatment response is 3 to 5 treatments.
DWD 81.09(3)(h)2. 2. Maximum treatment frequency is up to 5 times per week for the first one to 2 weeks decreasing in frequency until the end of the maximum treatment duration period in subd. 3.
DWD 81.09(3)(h)3. 3. Maximum treatment duration is 12 weeks.
DWD 81.09(3)(i) (i) Splints, braces, and other movement-restricting appliances. Bracing required for longer than 2 weeks shall be accompanied by active motion exercises to avoid stiffness and prolonged disability. All of the following guidelines apply to splints, braces, and other movement-restricting appliances:
DWD 81.09(3)(i)1. 1. Time for treatment response is 10 days.
DWD 81.09(3)(i)2. 2. Maximum treatment frequency is limited to intermittent use during times of increased physical stress or prophylactic use at work.
DWD 81.09(3)(i)3. 3. Maximum continuous duration is 8 weeks. Prophylactic use is allowed indefinitely.
DWD 81.09(3)(j) (j) Rest. Prolonged restriction of activity and immobilization are detrimental to a patient's recovery. Total restriction of use of an affected body part may not be prescribed for more than 2 weeks, unless rigid immobilization is required. In cases of rigid immobilization, active motion exercises at adjacent joints shall begin no later than 2 weeks after application of the immobilization.
DWD 81.09(4) (4)Active treatment modalities.
DWD 81.09(4)(a)(a) A health care provider shall use active treatment modalities as set forth in pars. (b) to (f). A health care provider's use of active treatment modalities may extend past the 12-week limitation on passive treatment modalities so long as the maximum treatment for the active treatment modality is not exceeded.
DWD 81.09(4)(b) (b) Education shall teach the patient about pertinent anatomy and physiology as it relates to upper extremity function for the purpose of injury prevention. Education includes training on posture, biomechanics, and relaxation. The maximum number of treatments is 3 visits which include an initial education and training session, and 2 follow-up visits.
DWD 81.09(4)(c) (c) Posture and work method training shall instruct the patient in the proper performance of job activities. Topics include proper positioning of the trunk, neck, and arms, use of optimum biomechanics in performing job tasks, and appropriate pacing of activities. Methods include didactic sessions, demonstrations, exercises, and simulated work tasks. The maximum number of treatments is 3 visits.
DWD 81.09(4)(d) (d) Worksite analysis and modification shall examine the patient's work station, tools, and job duties. A health care provider may make recommendations for the alteration of the work station, selection of alternate tools, modification of job duties, and provision of adaptive equipment. The maximum number of treatments is 3 visits.
DWD 81.09(4)(e) (e) Exercise, which is important to the success of a nonsurgical treatment program and a return to normal activity, shall include active patient participation in activities designed to increase flexibility, strength, endurance, or muscle relaxation. Exercise shall, at least in part, be specifically aimed at the musculature of the upper extremity. While aerobic exercise may be performed as adjunctive treatment, this shall not be the primary focus of the exercise program.
DWD 81.09(4)(f) (f) Exercises shall be evaluated to determine if the desired goals are being attained. Strength, flexibility, or endurance shall be objectively measured. A health care provider may objectively measure the treatment response as often as necessary for optimal care after the initial evaluation. Subdivisions 1. and 2. govern supervised and unsupervised exercise, except for computerized exercise programs and health clubs, which are governed by s. DWD 81.13.
DWD 81.09(4)(f)1. 1. `Guidelines for supervised exercise.' One goal of an exercise program shall be to teach the patient how to maintain and maximize any gains experienced from exercise. Self-management of the condition shall be promoted. All of the following guidelines apply to supervised exercise:
DWD 81.09(4)(f)1.a. a. Maximum treatment frequency is up to 3 times per week for 3 weeks and shall decrease with time until the end of the maximum treatment duration period in subd. 1. b.
DWD 81.09(4)(f)1.b. b. Maximum duration is 12 weeks.
DWD 81.09(4)(f)2. 2. `Guidelines for unsupervised exercise.' Unsupervised exercise shall be provided in the least intensive setting and may supplement or follow the period of supervised exercise.
DWD 81.09(5) (5)Therapeutic injections.
DWD 81.09(5)(a)(a) For purposes of this subsection, “therapeutic injections" include injections of trigger points, sympathetic nerves, peripheral nerves, and soft tissues. A health care provider may only give therapeutic injections in conjunction with active treatment modalities directed to the same anatomical site. A health care provider's use of injections may extend past the 12-week limitation on passive modalities, so long as the maximum treatment for injections in pars. (b) to (d) is not exceeded.
DWD 81.09(5)(b) (b) All of the following guidelines apply to trigger point injections:
DWD 81.09(5)(b)1. 1. Time for treatment response is within 30 minutes.
DWD 81.09(5)(b)2. 2. Maximum treatment frequency is once per week to any one site if there is a positive response to the first injection at that site. If subsequent injections at that site demonstrate diminishing control of symptoms or fail to facilitate objective functional gains, trigger point injections shall be redirected to other areas or discontinued. Only 3 injections to different sites per patient visit.
DWD 81.09(5)(b)3. 3. Maximum treatment is 4 injections to any one site over the course of treatment.
DWD 81.09(5)(c) (c) For purposes of this paragraph, “soft tissue injections" include injections of a bursa, tendon, tendon sheath, ganglion, tendon insertion, ligament, or ligament insertion. All of the following guidelines apply to soft tissue injections:
DWD 81.09(5)(c)1. 1. Time for treatment response is within one week.
DWD 81.09(5)(c)2. 2. Maximum treatment frequency is once per month to any one site if there is a positive response to the first injection. If subsequent injections demonstrate diminishing control of symptoms or fail to facilitate objective functional gains, then injections shall be discontinued. Only 3 injections to different sites per patient visit.
DWD 81.09(5)(c)3. 3. Maximum treatment is 3 injections to any one site over the course of treatment.
DWD 81.09(5)(d) (d) All of the following guidelines apply to injections for median nerve entrapment at the carpal tunnel:
DWD 81.09(5)(d)1. 1. Time for treatment response is within one week.
DWD 81.09(5)(d)2. 2. Maximum treatment frequency may permit repeat injection in one month if there is a positive response to the first injection. Only 3 injections to different sites per patient visit.
DWD 81.09(5)(d)3. 3. Maximum treatment is 2 injections to any one site over the course of treatment.
DWD 81.09(6) (6)Surgery.
DWD 81.09(6)(a)(a) A health care provider may perform surgery if it meets applicable guidelines in subs. (11) to (16) and s. DWD 81.12 (2).
DWD 81.09(6)(b) (b) In order to optimize the beneficial effect of surgery, postoperative therapy with active and passive treatment modalities may be provided, even if these modalities had been used in the preoperative treatment of the condition. In the postoperative period the maximum treatment duration with passive treatment modalities in a clinical setting from initiation of the first passive modality used, except bedrest or bracing, is as follows:
DWD 81.09(6)(b)1. 1. Sixteen weeks for rotator cuff repair, acromioclavicular ligament repair, or any surgery for a clinical category in this section that requires joint reconstruction.
DWD 81.09(6)(b)2. 2. Eight weeks for all other surgery for clinical categories in this section.
DWD 81.09(6)(c) (c) Repeat surgery shall also meet the guidelines of subs. (11) to (16) and s. DWD 81.12 (2).
DWD 81.09(7) (7)Chronic management. Chronic management of upper extremity disorders shall be provided according to the guidelines in s. DWD 81.13.
DWD 81.09(8) (8)Durable medical equipment.
DWD 81.09(8)(a)(a) A health care provider may direct the use of durable medical equipment only in the situations specified in pars. (b) to (e).
DWD 81.09(8)(b) (b) Splints, braces, straps, or supports may be necessary as specified in sub. (3) (i).
DWD 81.09(8)(c) (c) For patients using an electrical muscle stimulation device at home, the device and any required supplies are necessary within the guidelines of sub. (3) (e).
DWD 81.09(8)(d) (d) Exercise equipment for home use, including bicycles, treadmills, and stairclimbers, are necessary only as part of an approved chronic management program. This equipment is not necessary during initial nonsurgical care or during reevaluation and surgical therapy. If the employer has an appropriate exercise facility on its premises with the prescribed equipment the insurer may mandate use of that facility instead of authorizing purchase of the equipment for home use.
DWD 81.09(8)(d)1. 1. `Indications.' The patient is deconditioned and requires reconditioning that can be accomplished only with the use of the prescribed exercise equipment. A health care provider shall document specific reasons why the exercise equipment is necessary and may not be replaced with other activities.
DWD 81.09(8)(d)2. 2. `Requirements.' The use of the equipment shall have specific goals and there shall be a specific set of prescribed activities.
DWD 81.09(8)(e) (e) All of the following durable medical equipment is not necessary for home use for the upper extremity disorders specified in subs. (11) to (16):
DWD 81.09(8)(e)1. 1. Whirlpools, Jacuzzis, hot tubs, and special bath or shower attachments.
DWD 81.09(8)(e)2. 2. Beds, waterbeds, mattresses, chairs, recliners, and loungers.
DWD 81.09(9) (9)Evaluation of treatment by health care provider.
DWD 81.09(9)(a)(a) A health care provider shall evaluate at each visit whether the treatment is medically necessary and whether initial nonsurgical treatment is effective according to pars. (b) to (e). No later than the time for treatment response established for the specific modality in subs. (3) to (5), a health care provider shall evaluate whether the passive, active, injection, or medication treatment modality is resulting in progressive improvement as specified in pars. (b) to (e).
DWD 81.09(9)(b) (b) The patient's subjective complaints of pain or disability are progressively improving, as evidenced by documentation in the medical record of decreased distribution, frequency, or intensity of symptoms.
DWD 81.09(9)(c) (c) The objective clinical findings are progressively improving as evidenced by documentation in the medical record of resolution or objectively measured improvement in physical signs of injury.
DWD 81.09(9)(d) (d) The patient's functional status, especially vocational activity, is progressively improving, as evidenced by documentation in the medical record or documentation of work ability involving less restrictive limitations on activity.
DWD 81.09(9)(e) (e) If there is not progressive improvement in at least 2 categories specified in pars. (b) to (d), the modality shall be discontinued or significantly modified or a health care provider shall reconsider the diagnosis. The evaluation of the effectiveness of the treatment modality may be delegated to an allied health professional directly providing the treatment but remains the ultimate responsibility of the treating health care provider.
DWD 81.09(10) (10)Medication management.
DWD 81.09(10)(a)(a) Prescription of controlled substance medications scheduled under ch. 450, Stats., including opioids and narcotics, are necessary primarily for the treatment of severe acute pain. Therefore, these medications are not generally recommended in the treatment of patients with upper extremity disorders.
DWD 81.09(10)(b) (b) A health care provider shall document the rationale for the use of any scheduled medication. Treatment with nonscheduled medication may be appropriate during any phase of treatment and intermittently after all other treatment has been discontinued. The prescribing health care provider shall determine that ongoing medication is effective treatment for the patient's condition.
DWD 81.09(11) (11)Specific treatment guidelines for epicondylitis.
DWD 81.09(11)(a)(a) A health care provider shall use initial nonsurgical management for all patients with epicondylitis and this shall be the first phase of treatment.
DWD 81.09(11)(a)1. 1. The passive, active, injection, durable medical equipment, and medication treatment modalities and procedures specified in subs. (3), (4), (5), (8), and (10) may be used in sequence or simultaneously during the period of initial nonsurgical management depending on the severity of the condition. After the first week of treatment, initial nonsurgical care shall at all times include active treatment modalities under sub. (4).
DWD 81.09(11)(a)2. 2. Initial nonsurgical management shall be provided in the least intensive setting consistent with quality health care practices.
DWD 81.09(11)(a)3. 3. Except as provided in sub. (3), the use of passive treatment modalities in a clinic setting or requiring attendance by a health care provider for a period in excess of 12 weeks is not necessary.
DWD 81.09(11)(a)4. 4. Use of home-based treatment modalities with monitoring by the treating health care provider may continue for up to 12 months. At any time during this period the patient may be a candidate for chronic management if surgery is ruled out as an appropriate treatment.
DWD 81.09(11)(b) (b) If the patient continues with symptoms and objective physical findings after initial nonsurgical management and if the patient's condition prevents the resumption of the regular activities of daily life, including regular vocational activities, then surgical evaluation or chronic management is necessary. The purpose and goal of surgical evaluation is to determine whether surgery is necessary for the patient who has failed to recover with appropriate nonsurgical care or chronic management.
DWD 81.09(11)(b)1. 1. Surgical evaluation, if necessary, shall begin no later than 12 months after beginning initial nonsurgical management.
DWD 81.09(11)(b)2. 2. Surgical evaluation may include the use of appropriate laboratory and electrodiagnostic testing within the guidelines of sub. (1), if not already obtained during the initial evaluation. Repeat testing is not necessary unless there has been an objective change in the patient's condition that in itself would warrant further testing. Failure to improve with therapy does not, by itself, warrant further testing.
Loading...
Loading...
Published under s. 35.93, Stats. Updated on the first day of each month. Entire code is always current. The Register date on each page is the date the chapter was last published.